Emtricitabine, Efavirenz, and Didanosine in Pediatric HIV

Phase 2, open-label trial of emtricitabine in human immunodeficiency virus infection (HIV) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Proportion of Participants Who Developed Grade 3 or 4 Adverse Events Attributed to the Study Treatment at 144 weeks, Proportion of Participants With Suppression of HIV Viral Load to Less Than 400 Copies/ml at 16 weeks and 1 more. Started Aug 2001; status: completed.